Literature DB >> 27520083

The cannabinoid receptor agonist WIN55.212 reduces consequences of status epilepticus in rats.

Elena M Suleymanova1, Vitalia A Shangaraeva1, Clementina M van Rijn2, Lyudmila V Vinogradova3.   

Abstract

An acute brain insult can cause a spectrum of primary and secondary pathologies including increased risk for epilepsy, mortality and neurodegeneration. The endocannabinoid system, involved in protecting the brain against network hyperexcitability and excitotoxicity, is profoundly dysregulated by acute brain insults. We hypothesize that post-insult dysregulation of the endocannabinoid signaling may contribute to deleterious effects of an acute brain injury and potentiation of endocannabinoid transmission soon after an insult may reduce its pathological outcomes. Effects of an acute post-insult administration of the endocannabinoid receptor agonist WIN55,212-2 on early seizure occurrence, animal mortality and hippocampal cell loss were studied in the lithium-pilocarpine status model. A single dose of WIN55,212-2 (5mg/kg) administered four hours after the end of status epilepticus (SE) reduced the incidence of early seizures during the first two post-SE days though did not change their duration and latency. Brief 4-6-Hz spike-wave discharges appeared de novo in the latent post-SE period and the acute administration of WIN55,212-2 also reduced the incidence of the epileptiform events. A single dose of WIN55,212-2 administered soon after SE improved survival of animals and reduced cell loss in the dentate hilus but did not prevent appearance of spontaneous recurrent seizures in the chronic period. Thus, a brief pharmacological stimulation of the endocannabinoid system soon after a brain insult exerts beneficial effects on its pathological outcome though does not prevent epileptogenesis.
Copyright © 2016 IBRO. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  endocannabinoid system; epilepsy; mortality; neurodegeneration; spike–wave discharges; status epilepticus

Mesh:

Substances:

Year:  2016        PMID: 27520083     DOI: 10.1016/j.neuroscience.2016.08.004

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  6 in total

Review 1.  Therapeutic effects of cannabinoids in animal models of seizures, epilepsy, epileptogenesis, and epilepsy-related neuroprotection.

Authors:  Evan C Rosenberg; Pabitra H Patra; Benjamin J Whalley
Journal:  Epilepsy Behav       Date:  2017-02-09       Impact factor: 2.937

Review 2.  The Endocannabinoid System: A Potential Target for the Treatment of Various Diseases.

Authors:  Henry Lowe; Ngeh Toyang; Blair Steele; Joseph Bryant; Wilfred Ngwa
Journal:  Int J Mol Sci       Date:  2021-08-31       Impact factor: 6.208

3.  Early Gabapentin Treatment during the Latency Period Increases Convulsive Threshold, Reduces Microglial Activation and Macrophage Infiltration in the Lithium-Pilocarpine Model of Epilepsy.

Authors:  Alicia Rossi; Veronica Murta; Jerónimo Auzmendi; Alberto Javier Ramos
Journal:  Pharmaceuticals (Basel)       Date:  2017-11-28

4.  Cannabinoid antagonist SLV326 induces convulsive seizures and changes in the interictal EEG in rats.

Authors:  Martin F J Perescis; Natasja de Bruin; Liesbeth Heijink; Chris Kruse; Lyudmila Vinogradova; Annika Lüttjohann; Gilles van Luijtelaar; Clementina M van Rijn
Journal:  PLoS One       Date:  2017-02-02       Impact factor: 3.240

Review 5.  Anti-Epileptogenic Effects of Antiepileptic Drugs.

Authors:  Barbara Miziak; Agnieszka Konarzewska; Marzena Ułamek-Kozioł; Monika Dudra-Jastrzębska; Ryszard Pluta; Stanisław J Czuczwar
Journal:  Int J Mol Sci       Date:  2020-03-28       Impact factor: 5.923

6.  Low-Frequency Stimulation Prevents Kindling-Induced Impairment through the Activation of the Endocannabinoid System.

Authors:  Sina Khajei; Khadijeh Esmaeilpour; Javad Mirnajafi-Zadeh; Vahid Sheibani; Soheila Rezakhani; Yaser Masoumi-Ardakani
Journal:  Biomed Res Int       Date:  2021-06-16       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.